The market for radioligand therapies is expected to grow significantly in the coming years. This is due to the increasing number of patients who are ...

Company plans to initiate a pivotal phase 3 clinical trial of aglatimagene besadenovec (aglatimagene or CAN-2409) in patients with progressive, metastatic, non-squamous, non-small cell lung cancer ...